You are on page 1of 8

Helicobacter ISSN 1523-5378

doi: 10.1111/hel.12258

Treatment of Helicobacter pylori Infection 2015


Anthony OConnor,* Javier P. Gisbert,, Colm OMorain and Spiros Ladas
n Sanitaria
*Leeds Gastroenterology Institute, St. Jamess University Hospital, Leeds, UK, Department of Gastroenterology, Instituto de Investigacio
n Biome
dica en Red de Enfermedades Hepaticas y
Princesa (IIS-IP), Hospital Universitario de la Princesa, Madrid, Spain, Centro de Investigacio
Digestivas (CIBEREHD), Madrid, Spain, Department of Gastroenterology, Tallaght Hospital/Trinity College Dublin, Dublin, Ireland, Department of
Medicine & Gastroenterology, Medical School, Laiko University General Hospital of Athens, University of Athens, Athens, Greece

Keywords
peptic ulcer disease, resistance, compliance,
first line, second line, antimicrobial
susceptibility testing.
Reprint requests to: Anthony OConnor, Leeds
Gastroenterology Institute, Bexley Wing, St.
Jamess University Hospital, Leeds, UK. E-mail:
anthonyoconnor@nhs.net

Many interesting articles have been published from many parts of the world
over the last year assessing different issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last
year pertaining to the topic of treatment of H. pylori infection. The main
themes that emerge are assessing the efficacy of standard triple therapy, as
well as exploring new first-line treatments, mainly optimized nonbismuthand bismuth-containing quadruple therapies with some promising data also
emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied
parts of the world compared to recent years. There have also been advances
in the use of adjunctive therapies, especially probiotic therapies. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the
burden of diseases caused by the complications of this infection, including
dyspepsia, peptic ulcer disease, and gastric cancer.

Triple Therapy
A number of studies have been published this year, primarily from Asia, on standard triple therapy which
remains the regimen recommended in the majority of
published guidelines. A meta-analysis from China
showed suboptimal eradication rates in this part of the
world with a pooled rate of 74.5% which was inferior
when compared to sequential therapy with relative risk
(RR) = 0.863 [1]. Better, but still insufficient, eradication rates however were noted in Korea, with an overall eradication rate of 84% from 2005 to 2010 [2]. In
Japan, while rates remain clearly suboptimal, eradication rates by per-protocol (PP) analysis have not changed between 2001 and 2010 although there has been a
decline in eradication rates by intention-to-treat (ITT)
analysis [3]. Another Japanese group from a region of
higher clarithromycin resistance compared 7-day standard triple therapy with rabeprazole, amoxicillin, and
clarithromycin (RAC) to rabeprazole, amoxicillin, and
metronidazole (RAM). They found ITT eradication rates
of 73% in the RAC group and 91% in the RAM group
[4]. In other regions, a study in Nigeria found an eradication rate of 87% for triple therapy with no difference
between 7 and 10 days of treatment [5]. An interesting
study from Spain showed that when clarithromycin

54

susceptibility testing is carried out prior to treatment,


eradication rates reach 94% compared to 72% for
empiric treatment, based on a 10-day regimen [6]. Similar findings emerged from a Japanese study where
97% eradication was achieved when antimicrobial susceptibility testing was carried out prior to treatment,
and it was 95% eradication in a Korean study [7,8].
Another study from Spain examined the optimal
first-line eradication regimen for patients with penicillin allergy and reported ITT eradication rates
with omeprazoleclarithromycinmetronidazole of only
57% compared to 74% for PPIbismuthtetracycline
metronidazole, with equivalent rates of compliance and
adverse events. In this specific group for second-line
treatment, ITT eradication rate with omeprazoleclarithromycinlevofloxacin was 64% after failure of either
regimen [9].

Sequential Therapy
There have been several studies again this year examining sequential therapy, with the breadth of regions
where this regimen has been trialed growing. Over the
last year, several interesting randomized trials emerged
from East Asia. Sequential therapy consists of 5 days of
PPI therapy plus amoxicillin, followed by a further

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

Treatment of Helicobacter pylori

OConnor et al.

5 days of PPI with two other antibiotics, usually clarithromycin and metronidazole. A study from China
compared a 10-day sequential regimen with a quadruple bismuth-based regimen (esomeprazole, bismuth
subcitrate, tetracycline, and metronidazole) [10]. This
trial showed, by ITT analysis, eradication rates of 89%
for sequential and 93% for bismuth-based therapy
(p = .36). All patients in both arms who failed the firstline treatment were crossed over to the alternate regimen with 100% retreatment success. It was however
noted that the overall incidence of adverse events was
significantly higher in the bismuth-based group compared to the sequential therapy group (17 vs 8.1%). A
second Chinese randomized controlled trial (RCT) compared sequential therapy to standard triple therapy with
less impressive results [11]. In this study, there was no
significant difference between the eradication rates
achieved with standard triple therapy (66%) and
sequential therapy (72%). Although in this study
sequential therapy did have some advantages when
clarithromycin resistance was present, these were not
maintained when both clarithromycin and metronidazole resistance occurred. A third randomized study from
this part of the world, conducted in Taiwan, showed
that reversed sequential therapy where clarithromycin
and metronidazole were given first was equally effective [12]. In a retrospective study from Turkey, no significant difference was noted between eradication rates
with standard triple compared to sequential therapy (64
vs 71%), both being suboptimal [13]. In India, where
clarithromycin resistance rates are high, an RCT suggested that sequential therapy was more successful
when ciprofloxacin replaced clarithromycin (73.5 vs
66%) [14]. The systematic review evidence for sequential therapy was also updated this year, with a metaanalysis of 36 RCTs showing superior eradication rates:
84% for sequential therapy vs 75% for triple therapy,
with an RR for eradication of 1.14 (95% CI: 1.091.17)
[15].

Concomitant Therapy
Concomitant therapy is similar to sequential in that it
involves 1014 days of treatment with three antibiotics,
but in contrast to sequential therapy, all three antibiotics are taken along with the PPI for the full duration
of therapy. The concomitant regimen has been well
studied in both Europe and Asia over the last year. On
the basis that high-dose acid suppression and 14-day
duration of treatment can improve eradication rates by
up to 10%, a study from Spain looked at optimizing
therapy in this manner and comparing concomitant
(with PPI, amoxicillin, clarithromycin, and metronida-

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

zole) to triple therapy (with PPI, amoxicillin, and clarithromycin) and found better eradication rates for the
concomitant method (90 vs 81%) [16]. In Italy, a study
compared sequential therapy on a head-to-head basis
with concomitant and hybrid therapy and found no significant difference in eradication rates (90% for
sequential, 86 % for concomitant, and 83 % for hybrid
therapy), although a beta error cannot be ruled out,
due to the small sample size of this study [17].
Regarding Asian studies, in three separate studies
from Korea, two nonrandomized and one randomized,
a contrasting outcome was noted when sequential and
concomitant therapies were compared. In the randomized trial of 10-day concomitant versus sequential regimens, eradication was achieved in 79% with
concomitant therapy and 71% with sequential therapy
[18]. In the first nonrandomized study, the regimens
were compared to two different triple regimes with
eradication rates of 76% for triple therapy with clarithromycin, 84% for triple therapy with metronidazole,
84% for the sequential group, and 94% for the concomitant group [19]. In a second study, sequential and
concomitant therapies were compared to one another
with concomitant therapy having superior eradication
rates (94 vs 82%) [20]. Concomitant therapy also did
better than triple or sequential therapy in a head-tohead comparison from Taiwan with ITT eradication
rates of 94, 82, and 89%, respectively [21]. In Singapore however, no difference was noted between
sequential, triple, and concomitant therapies (84 vs 83
vs 88%) [22].
One of the major reservations that have been raised
regarding the concomitant regimen is related to the
potential for increased costs given the long duration of
therapy with more drugs. To this end, a prospective
randomized trial was carried out on 200 treatmentnave patients in Lebanon in which standard dose
versus half-dose concomitant nonbismuth quadruple
therapy (NBQT) with rabeprazole 20 mg, amoxicillin
500 mg, metronidazole 250 mg, and clarithromycin
250 mg was given for 7 days [23]. Eradication occurred
in 78% in both groups on ITT analysis with no reduction in adverse events; however, treatment was naturally cheaper with the half-dose regimen.

Hybrid Therapy
Hybrid therapy is an attempt to combine the principle
of the induction phase of sequential therapy as a means
of overcoming resistance with the benefits of four
drugs, which is the characteristic of the concomitant
therapy. It involves using PPI and amoxicillin for
14 days, while clarithromycin and metronidazole or

55

Treatment of Helicobacter pylori

OConnor et al.

equivalent are added for the final 7 days. A systematic


review of the efficacy and safety of hybrid therapy
showed ITT eradication rates with hybrid therapy, concomitant therapy, and sequential therapy were 89, 86,
and 85%, respectively, with no difference in compliance or adverse events [24]. Along similar lines to the
studies looking at the concomitant regime at lower
doses, a study was carried out looking at different durations of the hybrid regimen. Eradication rates, reported
PP, were similar: 95% for 10-day, 95% for 12-day, and
93% for 14-day hybrid therapies [25]. This result was
not reproduced by a study in Iran which showed unacceptably poor eradication rates for a 10-day hybrid
regime (78%) compared to 86% for 14 days of treatment [26].

Antimicrobial Resistance
Many studies on H. pylori primary antibiotic resistance
rates were carried out over the last year. They are summarized in Table 1 [2741]. Although molecular
in vitro testing gives a genotype that may not

correspond to the phenotype in vivo, broad themes that


do emerge are the increasing rates of clarithromycin
and also fluoroquinolone resistance. There is a trend
toward lower resistance rates in northern Europe compared to Asia. Another theme that has been addressed
is the emergence of H. pylori multidrug resistance.
In one study, multidrug resistance was detected in
26% of isolates, with 20% of them resistant to metronidazole and clarithromycin [27]. A systematic review
from Latin America showed 8% of isolates with dual
resistance to metronidazole and clarithromycin [30]. In
a large Chinese study looking at six antibiotics, double
resistance was noted in 27%, triple resistance in 17%,
quadruple resistance in 4.7%, quintuple resistance in
0.7%, and sextuple resistance in 0.3% [31]. An interesting study from Israel looked at the phenomenon of
secondary resistance in patients who had failed to
achieve eradication with first-line therapy [32]. Resistance to clarithromycin, metronidazole, and levofloxacin was present in 57, 64, and 5.1% of isolates,
respectively, with dual resistance to clarithromycin and
metronidazole in 40%. Over the study period

Table 1 Helicobacter pylori resistance to antibiotics in the studies published during the last year worldwide
Author

Study design

Region

Amoxycillin

Clarithromycin

Metronidazole

Furazolidone

Biernat [27]
Lee [28]
Okamura [29]

Prospective
Prospective
Prospective

Poland
Korea
Japan

0
17.2%
n/s

42%
n/s

n/s
n/s
n/s

Camargo [30]

Systematic
Review
Prospective
Prospective

Latin
America
China
Germany

4%

24%
37.3%
<30 years
3150
>51
12%

53%

6.8%
n/s

37.5%
6.7%

USA

Picoli [34]
Peretz [35]
Almeida [36]
Pandya [37]

CrossSectional
Prospective
Prospective
Prospective
Prospective

Brazil
Israel
Portugal
India

Cheng [38]

Prospective

Taiwan

Karczewska
[39]
Karamanolis
[40]
Phan [41]

Prospective

Poland

Prospective

Greece

Prospective

Vietnam

Song [31]
Wuppenhorst
[32]
Shiota [33]

Tetracycline

Rifabutin

8% (Levo)
n/s
n/s

0
n/s
n/s

0
n/s
n/s

3%

15% (Levo)

6%

n/s

67.2%
29.4%

n/s
n/s

33.5% (Levo)
n/s

3.5%
n/s

14.2%
n/s

16.4%

20.3%

n/s

31.3% (Levo)

0.8%

n/s

11.1%
22.3%
50%
58.8%

n/s
70.5%
34.4%
83.8%

n/s
n/s
n/s
13.8%

n/s
2.3%
0.6%
53.8%

n/s
n/s
n/s
n/s

9.7%

33.3%

n/s

n/s

n/s

n/s

n/s

n/s

5.5% (Cipro)
n/s
33.9% (Levo)
50% (Cipro)
23.8% (Levo)
8% (Cipro)
5.1% (Gemi)
8.5% (Moxi)
6.8% (Levo)
5.8% (Levo)

n/s

n/s

n/s

42%

n/s

n/s

n/s

n/s

42.4%

76.1%

n/s

n/s

n/s

1.9%
2.3%
0.6%
72.5%

1.1%

57.9%
34.5%
35.2%

Fluoroquinolones

5.3%
41.3% (Levo)

n/s stands for not specified.

56

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

Treatment of Helicobacter pylori

OConnor et al.

(20072014), clarithromycin resistance increased annually in a linear manner, while levofloxacin resistance
decreased annually and metronidazole resistance rates
were static. A very interesting study from Germany
looked at the difference in patterns of resistance based
on the topographic location of the gastric biopsies [42].
Discordant antibiotic susceptibility results were reported
between antrum and corpus isolates for different antibiotics in 15% of the patients and may account for some
treatment failures that occur even when treatment tailored to susceptibility is undertaken.

Bismuth Therapy
A study from Italy looked at the effect of adding bismuth to a 10-day triple therapy regimen consisting of
esomeprazole, amoxicillin, and doxycycline and found
that it significantly potentiated the eradication rates
achieving 89% (when 100 mg doxycycline was used)
and 92% (when 200 mg doxycycline was used) eradication rates by ITT analysis [43]. By contrast, the arms
of the study where bismuth was not used were less successful. The study design was to discontinue recruitment once six failures had been demonstrated in any
arm. This had been reached after 14 patients had been
enrolled in the arm with 100 mg doxycycline and 15
patients in the arm with 200 mg doxycycline.
A further study looked at the efficacy of bismuth as
a second-line regimen with metronidazole, tetracycline,
and PPI in comparison with dual therapy with moxifloxacin and amoxicillin. This revealed little difference
between the two combinations but a clear advantage
for prolonged durations of therapy for both, with eradication rates for 7-day bismuth, metronidazole, and
tetracycline of 66% compared to 71% for 14 days of
therapy (ITT) [44]. Following on from several recent
publications illustrating satisfactory eradication rates
with reduced-dose clarithromycin-based triple therapy
regimens, a letter published by a group from Lebanon
examined whether or not dose reduction of all components of a bismuth, tetracycline, esomeprazole, amoxicillin, and metronidazole would yield acceptable
eradication rates [45]. This was not the case, with
<65% achieving eradication (ITT). As a second-line
therapy in patients who have failed standard triple
therapy, one large study found quadruple therapy with
bismuth subcitrate potassium, omeprazole, metronidazole, and tetracycline hydrochloride, to yield ITT eradication rates ranging from 93 to 94% but with a high
rate of usually quite benign adverse events (67%) [46].
A separate study from Italy looked at second-line bismuth-based quadruple therapy with a different range
of antibiotics by randomizing participants taking

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

bismuth and PPI to two regimens, one with rifabutin


and minocycline and the other with tinidazole and
minocycline both for 10 days [47]. The rifabutin-based
regimen was more successful with an eradication rate
of 78% by ITT analysis compared to 52% for tinidazole-based therapy. In China, a bismuth-based quadruple regimen with furazolidone and tetracycline
achieved eradication in 91.7% of patients by ITT [48].
One novel study from Iran looked at prescribing bismuth-based quintuple therapy (bismuth, omeprazole,
tetracycline, and amoxicillin with either clarithromycin
or metronidazole) when quadruple therapy had failed
to achieve eradication [49]. They obtained eradication
rates of 87% when metronidazole was used and 77%
when it was clarithromycin. A similar agent to bismuth,
ecabet sodium, can also be used as a component of a
four-drug regimen against H. pylori. A meta-analysis
comparing regimens containing ecabet to triple therapies showed that the eradication rate in the ecabet-containing quadruple therapy group was higher than that
in the standard triple therapy group (85 vs 75%, OR
1.757 95%CI: 1.3072.362) [50].

Fluoroquinolones
A large number of studies looked at the role of fluoroquinolones, primarily levofloxacin, as both a first- and
second-line therapy against H. pylori. As a first-line
therapy, a systematic review was carried out of nine
RCTs including 1275 patients treated with levofloxacinbased triple therapy and 1237 patients with standard
triple therapy regimen. Eradication rate in the levofloxacin-based therapy group was 80% compared to 77%
in the standard triple therapy group (80 vs 77%). A difference was noted related to different geographic areas
with 7-day standard triple regimen being statistically
superior to 7-day levofloxacin-based scheme in the
Asian group (RR = 0.91, 95% CI = 0.860.97), but
levofloxacin-based triple therapy was superior regardless of treatment time in European countries
(RR = 1.15, 95% CI = 1.061.23) with no difference
observed regarding side effects [51]. A further systematic review reported the pooled OR by ITT for the levofloxacin triple regimen versus standard regimen was
1.28 (95% CI: 0.881.85) [52]. Two other original studies also compared fluoroquinolone-based triple therapy
to standard triple therapy. A study from Turkey noted
that the per-protocol (PP) eradication rate was 92% in
a levofloxacin triple therapy group, 92% in a moxifloxacin triple therapy group, and 82% in a clarithromycin triple therapy group, a statistically
significant difference for the combined fluoroquinolone-containing groups over clarithromycin [53].

57

Treatment of Helicobacter pylori

A study from Taiwan also showed a clear benefit for


levofloxacin-based 7-day triple therapy compared to
clarithromycin-based treatment (78 vs 58%) [54].
Levofloxacin can also be used as part of a sequential
regimen. In this context, a Korean study found no difference between eradication rates (ITT) for levofloxacin-based sequential therapy (78%) versus sequential
therapy (79%) [55].
Levofloxacin is also frequently used as a second-line
therapy. Two Taiwanese studies examined this question, and one study of levofloxacin as a 7-day secondline therapy in a triple therapy regimen with PPI and
amoxicillin revealed less impressive eradication rates of
79% (ITT) [56]. However, a separate Taiwanese study
reported more impressive results for 14-day levofloxacin-based triple therapy when compared to a 10-day
regimen in patients (67 vs 85% ITT) who had failed
standard triple therapy [57]. A large prospective multicenter study from Spain of 200 consecutive patients in
whom a standard triple therapy (PPIclarithromycin
amoxicillin) or a concomitant therapy had failed
revealed 90% eradication rate (ITT) for a second-line
quadruple regimen containing levofloxacin and bismuth, tetracycline, and metronidazole [58]. This represents a step forward as it includes levofloxacin in
second-line therapy as part of a quadruple rather than
triple therapy.
Moxifloxacin has also been studied as a second-line
therapy in patients having failed standard triple therapy. In one such study from Spain which was a
prospective, multicenter study, an 82% ITT eradication
rate was found for a 14-day regimen [59]. A study from
Korea compared moxifloxacin, a different fluoroquinolone therapy, against bismuth-based quadruple
therapy as second line [60]. This revealed poor eradication rates of 50% for moxifloxacin when used for
7 days compared to 78% for bismuth. Another study
also from Korea showed that as a second-line treatment
including moxifloxacin, of longer course, may be more
effective with 78% eradication for 2 weeks of therapy
compared to 63% for 7 days, by ITT analysis [61].

Dual Therapy
A few studies this year looked at the role of enhanced
dual therapy in eradication. A multicenter RCT from
China examined the role of high-dose dual therapy
(HDDT) with rabeprazole 20 mg and amoxicillin
750 mg, 4 times/day for 14 days with that of standard
and sequential therapies both empiric and second-line
treatment [62]. By ITT analysis, H. pylori was eradicated
in 95.3% of patients in the HDDT group, 85% in the
sequential group, and 81% in the standard triple

58

OConnor et al.

therapy group. As a second-line treatment, infection


was eradicated in 89% of patients with HDDT, 52% the
sequential group, and 79% with levofloxacin-based
therapy. A separate Chinese study revealed an ITT eradication rate of 90% for dual therapy with rabeprazole
and amoxicillin given three times daily for 14 days
[63]. Finally, a study from the United States looking at
the effect of extended dual release lansoprazole with
amoxicillin had to be discontinued early after 13
patients due to lack of efficacy [64].

Probiotics
Publications on probiotics in H. pylori eradication this
year can be divided into studies on various forms of
Lactobacilli species and systematic reviews. Regarding
Lactobacilli, one study found that L. plantarum XB7
secreted factors capable of modulating inflammation
during H. pylori infection, which may support a role for
it as an adjunctive therapy for treating H. pylori-associated disease [65]. Another suggested that Lactobacillus
reuteri was able to exert an inhibitory effect on H. pylori
growth and, when administered with eradication therapy, could lead to a significant reduction in antibioticassociated side effects, which may benefit compliance
[66]. L. reuteri has also been used as an eradication
agent per se, with pantoprazole in an open-label study,
but achieved a cure rate of only 14% by ITT analysis
[67]. Three meta-analyses have been published on the
role of probiotics as adjuvant treatments for H. pylori
infection. One showed pooled OR for the eradication
rates calculated by ITT analysis in the probiotic group
versus the control group of 1.67 (95%CI: 1.382.02)
with the incidence of diarrhea being significantly
reduced in the probiotic group (OR = 0.21 95%CI:
0.060.74) [68]. Two other reviews also noted very
similar findings with pooled eradication rates in probiotic supplementation groups significantly higher than
in controls and a significant difference between groups
in the overall incidence of side effects [69,70]. Interestingly, in one of the reviews, a subgroup analysis confirmed this finding only for four specific strains
(Lactobacillus acidophilus, Lactobacillus casei DN-114001,
Lactobacillus gasseri, and Bifidobacterium infantis 2036)
and for relatively ineffective antibiotherapies [69].

Furazolidone
Two studies this year examined the role of furazolidone
in H. pylori eradication. The largest study compared the
efficacy of furazolidone when used as part of a bismuth-based quadruple therapy to furazolidone as triple
therapy when given for 7 and 10 days in different arms

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

Treatment of Helicobacter pylori

OConnor et al.

of each group [71]. This revealed acceptable eradication


rates in excess of 80% for both 10-day arms but not for
7-day therapy with the best outcomes being for 10-day
quadruple bismuth-based therapy at 86% by ITT.
Although the standard dose for furazolidone has been
200 mg twice daily, another study from Iran showed
that eradication rates of 79% (still suboptimal) can be
obtained when lower doses (100 mg twice daily) are
used as part of a triple regimen compared to 58% for
clarithromycin in that cohort [72].

Reinfection and Recrudescence


Two studies looked at the issue of reinfection and
recrudescence after H. pylori eradication, which can be
difficult to distinguish between, over the last year. An
American study conducted in Alaska illustrated recurrence rates of 1222% over the course of 2-year follow-up, with rural dwellers (considered more likely to
be living in overcrowded accommodation) being at
greatest risk [73]. In a study from Korea, it was shown
that the rates of recurrence fall sharply 2 years after
treatment [74]. This would suggest that if reinfection or
recrudescence is to occur, it is likely to occur early.

does create difficulties for practitioners, as even in areas


of low prevalence many millions of people are infected
and a great deal of morbidity results from this. Whether
or not all the data obtained in high prevalence regions
can be readily extrapolated to lower prevalence ones is
a subject for discussion. Prescribing of H. pylori eradication therapy in many parts of the world is still in the
hands of gastroenterologist, and the data outlined
above illustrate that regimens being used are somewhat
haphazard. Clear recommendations are needed, and it
is hoped that the upcoming Maastricht V guidelines will
fill this void. Finally, to better understand resistance
patterns and the burden of both malignant and nonmalignant disease associated with H. pylori, adequate histologic sampling from both antrum and corpus needs to
be undertaken at endoscopy, and in the future, this
may be seen as a key performance indicator at endoscopy.

Acknowledgements and Disclosures


Competing interests: The authors declare no conflict of
interest.

References
Conclusion
There have been a many and varied number of studies
pertaining to H. pylori eradication treatment in the published literature over the last 12 months, often with
conflicting results, although several broad themes do
emerge. Outcomes for standard triple therapy have
been poor across most studies; however, when susceptibility testing is employed accurately, effective treatment
can still be delivered. The momentum behind sequential therapy as the regimen most likely to become preeminent has stalled somewhat, with more promising
results being noted in the published literature for both
bismuth- and nonbismuth (concomitant)-containing
quadruple therapies. In addition, a renewed interest in
HDDT based on amoxicillin delivered over prolonged
courses may help as the MIC is in a steady state and
amoxicillin resistance is rare. This may help overcome
some of the issues associated with rising rates of antibiotic resistance to macrolides and fluoroquinolones. Bismuth- and levofloxacin-based therapies have also
performed well as both primary and second-line eradication regimens and show promise when used in combination as a second-line treatment; however, issues
regarding resistance and availability may limit the
adoption of these agents in treatment protocols in some
regions. A concern is that most studies are coming from
areas with high infection rates. While not surprising, it

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

1 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a metaanalysis. World J Gastroenterol 2014;20:1497385.
2 Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-based
standard triple therapy can still be effective for Helicobacter pylori
eradication in some parts of the Korea. J Korean Med Sci
2014;29:12406.
3 Kawai T, Takahashi S, Suzuki H, Sasaki H, Nagahara A, Asaoka D,
et al. Changes in the first line Helicobacter pylori eradication rates
using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol 2014;29(Suppl 4):2932.
4 Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus
metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol 2015;49(6):46871.
5 Onyekwere CA, Odiagah JN, Igetei R, Emanuel AO, Ekere F, Smith
S. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori
eradication therapy: report of an efficacy study. World J Gastroenterol
2014;20:36159.
6 Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte
U, Fernandez-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance
regions. Eur J Gastroenterol Hepatol 2014;26:13804.
7 Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto
K, Furuta T. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of
acid secretion. Helicobacter 2014;19:3128.
8 Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, Lee WS, Joo
YE, Kim HS, Choi SK, Rew JS. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter
pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol 2014;109:1595602.
9 Gisbert JP, Barrio J, Modolell I, et al. Helicobacter pylori first-line and
rescue treatments in the presence of penicillin allergy. Dig Dis Sci
2015;60:45864.

59

Treatment of Helicobacter pylori

10 Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong
SY, Leung WK. Ten day sequential versus 10 day modified bismuth
quadruple therapy as empirical first-line and second-line treatment
for Helicobacter pylori in Chinese patients: an open label, randomised,
crossover trial. Gut 2014;63:14105.
11 Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for
Helicobacter pylori infection: a randomized multicenter trial. Am J
Gastroenterol 2014;109:53541.
12 Tsay FW, Wu DC, Kao SS, et al. Reverse sequential therapy
achieves a similar eradication rate as standard sequential therapy
for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter 2015;20:717.
13 Dolapcioglu C, Koc-Yesiltoprak A, Ahishali E, Kural A, Dolapcioglu
H, Soylu A, Dabak R. Sequential therapy versus standard triple
therapy in Helicobacter pylori eradication in a high clarithromycin
resistance setting. Int J Clin Exp Med 2014;7:
23248.
14 Chaabane NB, Al-Adhba HS. Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial. Indian J Gastroenterol 2015;34:6872.
15 Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential therapy or
standard triple therapy for Helicobacter pylori infection: an updated
systematic review. Am J Ther 2015; Jan 7 Epub ahead of print.
16 Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric
triple and concomitant therapy for Helicobacter pylori eradication in
clinical practice: the OPTRICON study. Aliment Pharmacol Ther
2015;41:5819.
17 De Francesco V, Hassan C, Ridola L, Giorgio F, Ierardi E, Zullo A.
Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63:74852.
18 Heo J, Jeon SW, Jung JT, et al. A randomised clinical trial of 10day concomitant therapy and standard triple therapy for Helicobacter
pylori eradication. Dig Liver Dis 2014;46:9804.
19 Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC,
Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
World J Gastroenterol 2015;21:3519.
20 Kim SY, Park DK, Kwon KA, Kim KO, Kim YJ, Chung J. Ten
day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication. Korean J Gastroenterol
2014;64:260.
21 Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS,
Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing
7-day triple, 10-day sequential, and 7-day concomitant therapies for
Helicobacter pylori infection. Antimicrob Agents Chemother
2014;58:593642.
22 Ang TL, Fock KM, Song M, Ang D, Kwek AB, Ong J, Tan J, Teo
EK, Dhamodaran S. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol 2015;30(7):11349.
23 Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar
C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging
the dogma: a randomized trial of standard vs. half-dose concomitant
non-bismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:17988.
24 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: Efficacy and safety of hybrid therapy for Helicobacter pylori
infection: a systematic review and meta-analysis. Helicobacter
2015;20:7988.
25 Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of
shortening 14-day hybrid therapy while maintaining an excellent
Helicobacter pylori eradication rate. Helicobacter 2014;19:20713.
26 Metanat HA, Valizadeh SM, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Bari Z. Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication: a randomized clinical trial.
Helicobacter 2015;20(4):299304.
27 Biernat MM, Poniewierka E, Baszczuk J, Czapla L, Kempi
nski R,
Ksiadzyna D, Grabi
nska J, Bi
nkowska A, Megraud F, Gosciniak G.

60

OConnor et al.

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Antimicrobial susceptibility of Helicobacter pylori isolates from Lower


Silesia, Poland. Arch Med Sci 2014;10:5059.
Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park
YS, Lee DH, Jung HC. Factors affecting first-line triple therapy of
Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:123543.
Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama
Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational
comparison. Helicobacter 2014;19:21420.
Camargo MC, Garca A, Riquelme A, Otero W, Camargo CA, Hernandez-Garca T, Candia R, Bruce MG, Rabkin CS. The problem of
Helicobacter pylori resistance to antibiotics: a systematic review in
Latin America. Am J Gastroenterol 2014;109:48595.
Song Z, Zhang J, He L, Chen M, Hou X, Li Z, Zhou L. Prospective
multi-region study on primary antibiotic resistance of Helicobacter
pylori strains isolated from Chinese patients. Dig Liver Dis
2014;46:107781.
W
uppenhorst N, Draeger S, St
uger HP, Hobmaier B, Vorreiter J, Kist
M, Glocker EO; ResiNet Study Group. Prospective multicentre study
on antimicrobial resistance of Helicobacter pylori in Germany. J
Antimicrob Chemother 2014;69:312733.
Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic
resistance of Helicobacter pylori among male United States Veterans.
Clin Gastroenterol Hepatol 2015.
Picoli SU, Mazzoleni LE, Fernandez H, De Bona LR, Neuhauss E,
Longo L, Prolla JC. Resistance to amoxicillin, clarithromycin and
ciprofloxacin of Helicobacter pylori isolated from Southern Brazil
patients. Rev Inst Med Trop Sao Paulo 2014;56:197200.
Peretz A, Paritsky M, Nasser O, Brodsky D, Glyatman T, Segal S, On
A. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. J Antibiot (Tokyo) 2014;67:5557.
Almeida N, Rom~aozinho JM, Donato MM, Luxo C, Cardoso O,
Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin Microbiol Infect 2014;20:112733.
Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of Helicobacter pylori in central Gujarat. Indian
J Med Microbiol 2014;32:40813.
Cheng A, Sheng WH, Liou JM, Wang HP, Wu MS, Lin JT, Chang
SC. Comparative in vitro antimicrobial susceptibility and synergistic
activity of antimicrobial combinations against Helicobacter pylori isolates in Taiwan. J Microbiol Immunol Infect 2015;48:729.
Karczewska E, Klesiewicz K, Wojtas-Bonior I, Skiba I, Sito E, Czajecki K, Zwoli
nska-Wciso M, Budak A. Levofloxacin resistance of
Helicobacter pylori strains isolated from patients in southern Poland,
between 20062012. Acta Pol Pharm 2014;71:47783.
Pandya HB, Agravat HH, Patel JS, Sodagar NR. The evolution of
Helicobacter pylori antibiotic resistance over 10 years in Greece. Digestion 2014;90:22931.
Phan TN, Santona A, Tran VH, Tran TN, Le VA, Cappuccinelli P,
Rubino S, Paglietti B. High rate of levofloxacin resistance in a
background of clarithromycin- and metronidazole resistant
Helicobacter pylori in Vietnam. Int J Antimicrob Agents 2015;45:
2448.
Selgrad M, Tammer I, Langner C, Bornschein J, Meile J, Kandulski
A, Varbanova M, Wex T, Schl
uter D, Malfertheiner P. Different
antibiotic susceptibility between antrum and corpus of the stomach,
a possible reason for treatment failure of Helicobacter pylori infection.
World J Gastroenterol 2014;20:1624551.
Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple
and Quadruple therapy with Doxycycline and bismuth for first-line
treatment of Helicobacter pylori infection: a pilot study. Helicobacter
2015. doi: 10.1111/hel.12209. [Epub ahead of print].
Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS.
Efficacy of 7-day and 14-day bismuth-containing quadruple therapy
and 7-day and 14-day Moxifloxacin-based triple therapy as secondline eradication for Helicobacter pylori Infection. Gut Liv 2015;9
(4):47885.

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

Treatment of Helicobacter pylori

OConnor et al.

45 Harb AH, El Reda ZD, Sarkis FS, Chaar HF, Sharara AI. Efficacy of
reduced-dose regimen of a capsule containing bismuth subcitrate,
metronidazole, and tetracycline given with amoxicillin and
esomeprazole in the treatment of Helicobacter pylori infection. United
European Gastroenterol J 2015;3:956.
46 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with
omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Aliment Pharmacol Ther 2014;40:1717.
47 Ierardi E, Giangaspero A, Losurdo G, Giorgio F, Amoruso A, De
Francesco V, Di Leo A, Principi M. Quadruple rescue therapy after
first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastrointestin Liver
Dis 2014;23:36770.
48 Zhang Y, Gao W, Cheng H, Zhang X, Hu F. Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.
Helicobacter 2014;19:3826.
49 Mansour-Ghanaei F, Joukar F, Naghipour MR, Forouhari A, Saadat
SM. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol 2015;21:6616.
50 Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y,
Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and metaanalysis. Helicobacter 2014;19:37281.
51 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an
alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014;49:52838.
52 Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin
and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf 2014;23:44355.
53 Rakici H, Ayaz T, Akdogan RA, Bedir R. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Digestion 2014;90:2614.
54 Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacinamoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res
Int 2014;2014:158520.
55 Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection
in Korea. Dig Liver Dis 2015;47:1148.
56 Liang CM, Cheng JW, Kuo CM, Chang KC, Wu KL, Tai WC, Chiu
KW, Chiu SS, Lin MT, Hu TH, Chuah SK. Levofloxacin-containing
second-line anti-Helicobacter pylori eradication in Taiwanese realworld practice. Biomed J 2014;37:32630.
57 Tai WC, Lee CH, Chiou SS, et al. The clinical and bacteriological
factors for optimal levofloxacin-containing triple therapy in secondline Helicobacter pylori eradication. PLoS ONE 2014;9:e105822.
58 Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori secondline rescue therapy with levofloxacin- and bismuth-containing
quadruple therapy, after failure of standard triple or non-bismuth
quadruple treatments. Aliment Pharmacol Ther 2015;41:76875.
59 Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, highdose proton pump inhibitor, moxifloxacin triple Helicobacter pylori

2015 John Wiley & Sons Ltd, Helicobacter 20 (Suppl. S1): 5461

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

therapy after failure of standard triple or non-bismuth quadruple


treatments. Dig Liver Dis 2015;47:10813.
Chung KH, Lee DH, Jin E, Cho Y, Seo JY, Kim N, Jeong SH, Kim
JW, Hwang JH, Shin CM. The efficacy of moxifloxacin-containing
triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. Gut Liv
2014;8:60511.
Kang KK, Lee DH, Oh DH, Yoon H, Shin CM, Park YS, Kim N, Jung
HC. Helicobacter pylori eradication with moxifloxacin-containing
therapy following failed first-line therapies in South Korea. World J
Gastroenterol 2014;20:69328.
Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior
to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895905.
Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual
therapy for primary treatment of Helicobacter pylori infection: a
prospective randomized study in Shanghai, China. J Dig Dis
2014;15:6227.
Attumi TA, Graham DY. High-dose extended-release lansoprazole
(dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori
infections. Helicobacter 2014;19:31922.
Thiraworawong T, Spinler JK, Werawatganon D, Klaikeaw N, Venable SF, Versalovic J, Tumwasorn S. Anti-inflammatory properties
of gastric-derived Lactobacillus plantarum XB7 in the context of Helicobacter pylori infection. Helicobacter 2014;19:14455.
Francavilla R, Polimeno L, Demichina A, et al. Lactobacillus reuteri
strain combination in Helicobacter pylori infection: a randomized,
double-blind, placebo-controlled study. J Clin Gastroenterol
2014;48:40713.
Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus
reuteri in the treatment of Helicobacter pylori infection. Intern Emerg
Med 2014;9:64954.
Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of
probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:1801321.
Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics
supplementation on Helicobacter pylori eradication rates and side
effects during eradication therapy: a meta-analysis. PLoS ONE
2014;9:e111030.
Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and
safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med 2015;9:70716.
Xie Y, Zhu Y, Zhou H, et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J Gastroenterol 2014;20:1141521.
Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, Oveisi S,
Kazemifar AM. Low dose furazolidone for eradication of H. pylori
instead of clarithromycin: a clinical trial. Glob J Health Sci
2014;7:2359.
Bruce MG, Bruden DL, Morris JM, et al. Reinfection after successful
eradication of Helicobacter pylori in three different populations in
Alaska. Epidemiol Infect 2015;143:123646.
Kim SY, Hyun JJ, Jung SW, Koo JS, Yim HJ, Lee SW. Helicobacter
pylori recurrence after first- and second-line eradication therapy in
Korea: the problem of recrudescence or reinfection. Helicobacter
2014;19:2026.

61

You might also like